Wanbury Ltd Upgraded to Buy on Strong Technical and Financial Performance

Quality Assessment: Strong Operational Metrics and Profitability

Wanbury’s quality rating has been bolstered by its consistent operational performance and profitability improvements. The company reported a remarkable operating profit growth at an annualised rate of 107.56%, underscoring its ability to scale earnings efficiently. The latest nine-month PAT stood at ₹44.43 crores, reflecting a staggering 332.20% increase, signalling strong bottom-line momentum.

Return on Capital Employed (ROCE) is notably high at 33.3%, indicating effective utilisation of capital to generate profits. Furthermore, the operating profit to interest coverage ratio for the quarter reached a peak of 3.68 times, demonstrating Wanbury’s improved capacity to service debt obligations comfortably. Despite a relatively high debt-equity ratio of 1.83 times at half-year, this is a marked improvement from the company’s historical average of 3.36 times, suggesting a gradual deleveraging trend.

However, investors should remain cautious of the high promoter share pledge, which stands at 86.69%, a factor that could exert downward pressure on the stock in volatile markets. Additionally, the company’s net sales growth over the past five years has been moderate at 14.16% annually, indicating room for improvement in top-line expansion.

Valuation: Attractive Discounts and Compelling Multiples

Wanbury’s valuation profile has become increasingly compelling, contributing to the upgrade. The stock currently trades at ₹257.70, below its 52-week high of ₹329.00 but comfortably above the 52-week low of ₹162.00. Its enterprise value to capital employed ratio stands at a modest 4.8, signalling undervaluation relative to capital base and earnings potential.

Compared to sector peers, Wanbury is trading at a discount to historical valuation averages, enhancing its appeal for value-conscious investors. The company’s PEG ratio is an exceptionally low 0.1, reflecting the stock’s price relative to its earnings growth rate, which is highly favourable given the 252.3% profit increase over the past year despite a 15.65% decline in share price during the same period.

This divergence between earnings growth and price performance suggests a potential market mispricing, which the recent upgrade aims to highlight. Investors seeking long-term growth at reasonable valuations may find Wanbury’s current price levels attractive.

Financial Trend: Consistent Quarterly Gains Amid Mixed Long-Term Returns

Wanbury’s financial trend has been a key driver of the rating upgrade. The company has delivered positive results for three consecutive quarters, signalling operational stability and growth momentum. The latest quarterly data highlights a strong operating profit surge and a PAT growth rate that outpaces many peers in the Pharmaceuticals & Biotechnology sector.

When analysing returns, Wanbury’s stock has outperformed the Sensex and broader market indices over longer horizons. Over three years, the stock has generated an extraordinary 440.70% return compared to the Sensex’s 21.82%, and over ten years, the stock’s return of 461.44% dwarfs the Sensex’s 196.07%. However, the last one-year period has been challenging, with the stock declining 15.65% against the Sensex’s 8.36% fall, reflecting short-term volatility and market headwinds.

This mixed performance underscores the importance of a long-term investment horizon when considering Wanbury, as its fundamental growth story remains intact despite recent price fluctuations.

Technicals: Bullish Momentum Signals Upgrade

The technical outlook for Wanbury has improved significantly, prompting the upgrade in the technical grade from mildly bullish to bullish. Key indicators support this positive shift:

• MACD: Weekly readings are bullish, although monthly signals remain mildly bearish, suggesting near-term momentum is strengthening.
• Bollinger Bands: Both weekly and monthly charts show bullish trends, indicating price volatility is favouring upward movement.
• Moving Averages: Daily moving averages are bullish, reinforcing the positive price trajectory.
• KST (Know Sure Thing): Weekly readings are bullish, while monthly remain mildly bearish, aligning with MACD signals.
• On-Balance Volume (OBV): Weekly OBV is mildly bullish, reflecting accumulation by investors.

Price action today supports this technical optimism, with the stock rising 1.98% to ₹257.70, hitting an intraday high of ₹260.00. The 52-week trading range of ₹162.00 to ₹329.00 provides ample room for upside, especially given the improving technical backdrop.

Risks and Considerations

Despite the positive upgrade, investors should weigh certain risks. The company’s average debt-equity ratio remains high at 3.36 times, which could constrain financial flexibility. The substantial promoter share pledge of 86.69% adds a layer of risk, as forced selling in adverse market conditions could amplify price declines.

Moreover, Wanbury’s underperformance relative to the BSE500 index over the past year, with a return of -15.65% versus the index’s -2.09%, highlights vulnerability to market sentiment and sector-specific challenges. The moderate net sales growth rate of 14.16% over five years also suggests that top-line expansion is not as robust as profit growth, which may raise questions about sustainability.

Conclusion: Upgrade Reflects Balanced Optimism

The upgrade of Wanbury Ltd’s investment rating from Hold to Buy is a reflection of its improved quality metrics, attractive valuation, positive financial trends, and strengthening technical signals. While the company faces challenges related to debt levels and promoter pledges, its operational profitability and long-term returns present a compelling case for investors with a medium to long-term horizon.

With a Mojo Score of 71.0 and a Buy grade, Wanbury stands out as a micro-cap pharmaceutical stock with significant upside potential, especially as it continues to deliver consistent quarterly results and benefits from a bullish technical setup. Investors should monitor debt reduction efforts and market conditions closely but may consider this upgrade as a signal to re-evaluate Wanbury’s place in their portfolios.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →